Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FHTX 
Foghorn Therapeutics Inc (FHTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: FHTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.67
1 Year Target Price $11.67
| 5 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.29% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 293.39M USD | Price to earnings Ratio - | 1Y Target Price 11.67 |
Price to earnings Ratio - | 1Y Target Price 11.67 | ||
Volume (30-day avg) 8 | Beta 3.05 | 52 Weeks Range 2.94 - 10.25 | Updated Date 09/15/2025 |
52 Weeks Range 2.94 - 10.25 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -279.17% |
Management Effectiveness
Return on Assets (TTM) -20.7% | Return on Equity (TTM) -470.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 118423539 | Price to Sales(TTM) 12.14 |
Enterprise Value 118423539 | Price to Sales(TTM) 12.14 | ||
Enterprise Value to Revenue 4.9 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 56530000 | Shares Floating 26763549 |
Shares Outstanding 56530000 | Shares Floating 26763549 | ||
Percent Insiders 18.68 | Percent Institutions 72.72 |
Upturn AI SWOT
Foghorn Therapeutics Inc
Company Overview
History and Background
Foghorn Therapeutics Inc. was founded in 2016. The company focuses on discovering and developing a new class of medicines targeting genetically determined drivers of cancer, based on the chromatin regulatory system. They went public in 2020.
Core Business Areas
- Gene Traffic Control Platform: Foghorn's proprietary Gene Traffic Control platform is used to identify and validate novel drug targets within the chromatin regulatory system.
- Drug Discovery and Development: The company is engaged in the discovery and development of small molecule and protein degrader therapeutics targeting cancer.
- Partnerships: Foghorn collaborates with other pharmaceutical companies to advance their drug discovery and development programs.
Leadership and Structure
The leadership team includes experienced executives in drug discovery and development. The organizational structure includes research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- FOG-001: A BRD9 degrader in Phase 1 clinical trial for relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Competitors include companies developing other AML/MDS therapies like AbbVie, Novartis, and Bristol Myers Squibb.
- FOG-002: A selective CBP/p300 inhibitor in Phase 1 clinical trial for AR-V7 positive metastatic castration-resistant prostate cancer (mCRPC). Competitors include companies developing mCRPC therapies like Johnson & Johnson and Pfizer.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with a focus on developing novel therapies for cancer. This includes gene therapies, targeted therapies, and immunotherapies.
Positioning
Foghorn Therapeutics is positioned as an innovator in the field of chromatin regulatory system-based therapeutics, targeting specific genetic drivers of cancer. Their competitive advantage lies in their proprietary platform and focus on previously undruggable targets.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is substantial, estimated to be hundreds of billions of dollars globally. Foghorn is focused on specific segments within this market, targeting genetically defined cancers where their approach has a higher probability of success. Exact TAM for their specific targets requires market specific estimates. The market capitalization gives an indication of position within this TAM
Upturn SWOT Analysis
Strengths
- Proprietary Gene Traffic Control platform
- Novel target identification
- Strong scientific team
- Strategic partnerships
Weaknesses
- Early stage clinical development
- Reliance on partnerships for funding
- High cash burn rate
- Limited commercial experience
Opportunities
- Expansion of pipeline to other cancer types
- Successful clinical trial outcomes
- Out-licensing or partnering of assets
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Patent challenges
- Funding constraints
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- BMY
- JNJ
- PFE
- MRTX
- GILD
Competitive Landscape
Foghorn has a competitive advantage in its proprietary Gene Traffic Control platform. However, it faces competition from larger, more established pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by the expansion of the pipeline and the progress of clinical trials.
Future Projections: Future growth is dependent on the success of clinical trials and partnerships. Analyst estimates can provide projections, though early-stage biotechs have very uncertain projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for FOG-001 and FOG-002 and forging or extending partnerships.
Summary
Foghorn Therapeutics is an early-stage biotech company with a novel approach to cancer therapeutics. Their proprietary platform offers a potential advantage, but they face significant risks related to clinical trial success and funding. Positive clinical data and strategic partnerships are critical for future success. The company needs to carefully manage its cash burn while advancing its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Foghorn Therapeutics Inc. Investor Relations
- SEC Filings
- Company press releases
- Analyst reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Foghorn Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-10-23 | President, CEO & Director Mr. Adrian H. B. Gottschalk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 112 | Website https://foghorntx.com |
Full time employees 112 | Website https://foghorntx.com | ||
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.